

B. In the Claims

Please cancel claims 1 to 21 without prejudice.

Upon entry of the present amendment, the status of the claims will be as follows:

Claims 1-21 (canceled)

22. (original) A method for generating a chimeric therapeutic organism from a pathogenic organism that possesses in the wild-type an integrin-like protein with an I domain, said method comprising:

replacing the I domain in the integrin-like protein of the pathogenic organism with an antibody fragment that binds to a disease-associated antigen on a diseased cell;
wherein the wild-type pathogenic organism undergoes virulent transformation by binding of the I domain of the surface integrin-like protein to a cell, and wherein the chimeric therapeutic organism undergoes virulent transformation by binding of the antibody fragment to the disease-associated antigen on the cell.

23. (original) The method of claim 22, wherein the pathogenic organism is *C. albicans* and wherein the method further comprises disabling the wild-type CAFTR gene in the *C. albicans*, and

introducing a DNA construct comprising a wild-type CAFTR gene under the control of a EFG1p response element,

wherein binding of the antibody fragment to the disease-associated antigen triggers expression of the CAFTR gene in the DNA construct and filamentous transformation in the chimeric pathogenic *C. albicans*.

In re Application of:
Duncan Odom
Application No.: Not Yet Assigned
Filed: September 26, 2003
Page 4

PATENT
Attorney Docket No.: CIT1360-3

24. (original) The method of claim 23, wherein the antibody fragment is a single chain antibody.

25. (original) The method of claim 23, wherein the antibody fragment binds to an antigen on a tumor cell.

26. (original) The method of claim 25, wherein the disease-associated antigen is contained in an abnormal surface protein of the tumor cell.